Tags

Type your tag names separated by a space and hit enter

Intraplaque verapamil injection for treatment of Peyronie's disease.
J La State Med Soc. 1998 Sep; 150(9):431-4.JL

Abstract

We report our findings on the effects of intraplaque injection of verapamil for the treatment of Peyronie's disease. We followed 11 men with Peyronie's disease in a nonrandomized constant dose study. During our study, four men received testosterone supplementation; five received vitamin E and/or potassium aminobenzoate (potaba) concurrent with verapamil; two received injections of verapamil only. Plaque size decreased significantly in 7 of 11 patients (55%); softening occurred in 6 (55%); 4 of 8 patients (50%) had decreased curvature. Deformities and symptoms did not recur in any patients who reported improvement. Three of 11 (27%) patients failed treatment and elected to undergo surgical correction. All four (100%) of our study participants with pain had complete resolution after intraplaque verapamil injection compared with Levine et al's 91%. We have demonstrated that intraplaque verapamil injection is a promising treatment for Peyronie's disease in that it may circumvent surgical intervention and may be used with concurrent therapies.

Authors+Show Affiliations

Tulane University School of Medicine, New Orleans, La., USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

9785755

Citation

Lasser, A, et al. "Intraplaque Verapamil Injection for Treatment of Peyronie's Disease." The Journal of the Louisiana State Medical Society : Official Organ of the Louisiana State Medical Society, vol. 150, no. 9, 1998, pp. 431-4.
Lasser A, Vandenberg TL, Vincent MJ, et al. Intraplaque verapamil injection for treatment of Peyronie's disease. J La State Med Soc. 1998;150(9):431-4.
Lasser, A., Vandenberg, T. L., Vincent, M. J., & Hellstrom, W. J. (1998). Intraplaque verapamil injection for treatment of Peyronie's disease. The Journal of the Louisiana State Medical Society : Official Organ of the Louisiana State Medical Society, 150(9), 431-4.
Lasser A, et al. Intraplaque Verapamil Injection for Treatment of Peyronie's Disease. J La State Med Soc. 1998;150(9):431-4. PubMed PMID: 9785755.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intraplaque verapamil injection for treatment of Peyronie's disease. AU - Lasser,A, AU - Vandenberg,T L, AU - Vincent,M J, AU - Hellstrom,W J, PY - 1998/10/24/pubmed PY - 1998/10/24/medline PY - 1998/10/24/entrez SP - 431 EP - 4 JF - The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society JO - J La State Med Soc VL - 150 IS - 9 N2 - We report our findings on the effects of intraplaque injection of verapamil for the treatment of Peyronie's disease. We followed 11 men with Peyronie's disease in a nonrandomized constant dose study. During our study, four men received testosterone supplementation; five received vitamin E and/or potassium aminobenzoate (potaba) concurrent with verapamil; two received injections of verapamil only. Plaque size decreased significantly in 7 of 11 patients (55%); softening occurred in 6 (55%); 4 of 8 patients (50%) had decreased curvature. Deformities and symptoms did not recur in any patients who reported improvement. Three of 11 (27%) patients failed treatment and elected to undergo surgical correction. All four (100%) of our study participants with pain had complete resolution after intraplaque verapamil injection compared with Levine et al's 91%. We have demonstrated that intraplaque verapamil injection is a promising treatment for Peyronie's disease in that it may circumvent surgical intervention and may be used with concurrent therapies. SN - 0024-6921 UR - https://wwww.unboundmedicine.com/medline/citation/9785755/Intraplaque_verapamil_injection_for_treatment_of_Peyronie's_disease_ DB - PRIME DP - Unbound Medicine ER -